BICD2 Gene Spinal Muscular Atrophy Lower Extremity Autosomal Dominant Type 2 Genetic Test
Test Name: BICD2 Gene Spinal muscular atrophy lower extremity autosomal dominant type 2 Genetic Test
Components: Blood or Extracted DNA or One drop Blood on FTA Card
Price: 4400.0 AED
Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery: 3 to 4 Weeks
Method: NGS Technology
Test type: Neurological Disorders
Doctor: Neurologist
Test Department: Genetics
Pre Test Information: Clinical History of Patient who is going for BICD2 Gene Spinal muscular atrophy, lower extremity, autosomal dominant, type 2 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with BICD2 Gene Spinal muscular atrophy, lower extremity, autosomal dominant, type 2.
Test Details: The BICD2 gene is associated with a genetic condition called spinal muscular atrophy, lower extremity, autosomal dominant, type 2 (SMALED2). This condition is characterized by muscle weakness and atrophy, particularly in the lower extremities. It is inherited in an autosomal dominant manner, meaning that a person only needs to inherit one copy of the mutated gene from either parent to develop the condition. NGS (Next-Generation Sequencing) genetic testing refers to a type of genetic testing that utilizes advanced sequencing technologies to analyze multiple genes simultaneously. In the context of SMALED2, NGS genetic testing can be used to identify mutations or variations in the BICD2 gene that may be responsible for the condition. This testing can help confirm a diagnosis, provide information about the specific genetic variant causing the condition, and assist in genetic counseling and family planning. It is important to note that genetic testing should be conducted and interpreted by a qualified healthcare professional or genetic counselor who can provide accurate and comprehensive information about the results and their implications.
Test Name | BICD2 Gene Spinal muscular atrophy lower extremity autosomal dominant type 2 Genetic Test |
---|---|
Components | |
Price | 4400.0 AED |
Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card o |
Report Delivery | 3 to 4 Weeks |
Method | NGS Technology |
Test type | Neurological Disorders |
Doctor | Neurologist |
Test Department: | Genetics |
Pre Test Information | Clinical History of Patient who is going for BICD2 Gene Spinal muscular atrophy, lower extremity, autosomal dominant, type 2 NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with BICD2 Gene Spinal muscular atrophy, lower extremity, autosomal dominant, type 2 |
Test Details |
The BICD2 gene is associated with a genetic condition called spinal muscular atrophy, lower extremity, autosomal dominant, type 2 (SMALED2). This condition is characterized by muscle weakness and atrophy, particularly in the lower extremities. It is inherited in an autosomal dominant manner, meaning that a person only needs to inherit one copy of the mutated gene from either parent to develop the condition. NGS (Next-Generation Sequencing) genetic testing refers to a type of genetic testing that utilizes advanced sequencing technologies to analyze multiple genes simultaneously. In the context of SMALED2, NGS genetic testing can be used to identify mutations or variations in the BICD2 gene that may be responsible for the condition. This testing can help confirm a diagnosis, provide information about the specific genetic variant causing the condition, and assist in genetic counseling and family planning. It is important to note that genetic testing should be conducted and interpreted by a qualified healthcare professional or genetic counselor who can provide accurate and comprehensive information about the results and their implications. |